8:19 PM · 14 October 2025

Salesforce announces partnerships with OpenAI and Anthropic🚨

Key takeaways
Salesforce
Stocks
CRM.US, salesforce.com Inc
-
-
Key takeaways
  • Salesforce announces high-profile cooperation with two AI giants 
  • Despite that - there is little to no gain in price 
  • Fundamentals look strong, but technical indicators - not so much 

Salesforce announced on October 14 two strategic extensions of collaboration – with OpenAI and Anthropic – aimed at deepening the integration of AI solutions within the Agentforce 360 ecosystem.

The collaboration with OpenAI involves connecting the Agentforce 360 platform with ChatGPT, enabling users to search sales data, analyze customer conversations, and create visualizations in Tableau using simple text queries. Additionally, the companies will offer tools for building AI agents and prompts using the latest OpenAI models, including GPT-5, as well as a new sales feature in ChatGPT for Salesforce customers, providing full control over data and customer relationships.
Simultaneously, Salesforce announced an extension of collaboration with Anthropic, focusing on delivering AI solutions for regulated and data-sensitive sectors. The Claude model will become the foundation for the Agentforce 360 platform, with initial implementations targeting the financial sector. Both companies also plan deeper integration of Claude with Slack, allowing users access to AI tools directly within team collaboration applications.
Salesforce has been performing very well in recent years, consistently increasing its scale of operations and revenues year over year. The company is executing a thoughtful development strategy in the area of artificial intelligence, which is already starting to yield tangible results in the form of increased productivity and improved margins. AI could become a kind of operational leverage for Salesforce, allowing it to scale both costs and profits.
Despite dynamic growth, the company's valuation remains relatively conservative by technology industry standards:

  • P/E ratio is around 36
  • Price to sales is 5
  • Price to book value is 3

Despite this optimistic backdrop, Salesforce shares lost about 15% of their value in 2025. Moreover, even today's announcement of extended collaboration with OpenAI failed to reverse the negative trend. The company's stock continues to decline during the session, losing over 1% today. Not long ago, similar announcements of any collaboration with OpenAI could trigger double-digit increases in technology companies' valuations. Have investors stopped believing in the "magic" of artificial intelligence, or is Salesforce's fundamental situation weaker than a superficial analysis suggests? This is a question that will likely be answered in the upcoming quarterly results.
CRM.US (D1)

 

Source: xStation5
The technical situation on the chart looks dramatic for buyers. The company remains in a downward trend that has persisted for almost a year and has been repeatedly confirmed by price bouncing off the trend line with periodic supply gaps. Moreover, in April this year, we observed the so-called "Death Cross," which is the crossing of the EMA50 and EMA200 averages, followed quickly by the "Bearish Crossover," which is the crossing of EMA200 by EMA100 (from above). The price is inexorably approaching the support level at 229 more frequently, and soon it will intersect with the trend line. Buyers must hurry to reverse the trend if they want to prevent a correction to the level of 194 dollars — the minimum from 2 years ago.

7 October 2025, 8:57 PM

⏬US100 is down 0.5% on Oracle news

6 October 2025, 6:06 PM

Stock of the Month: Will Meta win the AI ​​race?

14 October 2025, 7:25 PM

Intel down 5% 📉

14 October 2025, 6:56 PM

JPMorgan, Goldman Sachs, and Citigroup: Sector Overview and Challenges

The material on this page does not constitute as financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other particular needs.
All the information provided, including opinions, market research, mathematical results and technical analyses published on the website or transmitted to you by other means is provided for information purposes only and should in no event be interpreted as an offer of, or solicitation for, a transaction in any financial instrument, nor should the information provided be construed as advice of legal or fiscal nature.
Any investment decisions you make shall be based exclusively on your level of understanding, investment objectives, financial situation or any other particular needs. Any decision to act on information published on the website or transmitted to you by other means is entirely at your own risk. You are solely responsible for such decisions.
If you are in doubt or are not sure that you understand a particular product, instrument, service, or transaction, you should seek professional or legal advice before trading.
Investing in OTC Derivatives carries a high degree of risk, as they are leveraged based products and often small movements in the market could lead to much larger movements in the value of your investment and this could work against you or for you. Please ensure that you fully understand the risks involved, taking into account your investments objectives and level of experience, before trading, and if necessary, seek independent advice.

Join over 1 700 000 investors from around the world